Introduction
Hemophilia and von Willebrand disease represent the most prevalent congenital bleeding conditions. Traditionally, managing these disorders has centered on replacing the deficient coagulation factor to prevent or address bleeding episodes. However, advancements in technology and understanding of hemostasis have led to the emergence of promising therapeutic avenues. This article will explain the emerging treatment for rare blood disorders.
What Are Rare Blood Disorders?
Rare blood disorders, also known as hematologic disorders or hematological conditions, are a group of diseases that affect the blood, bone marrow, lymph nodes, and spleen. These disorders are characterized by abnormalities in the production, function, or lifespan of blood cells or blood components. Some examples of rare blood disorders include:
1. Hemophilia: Hemophilia is a genetic disorder characterized by a deficiency or absence of clotting factors in the blood. Hemophilia A (caused by factor VIII [FVIII] deficiency) and B (due to FIX deficiency) are severe bleeding disorders affecting approximately 1 in 5000 and 1 in 20,000 males, respectively. Von Willebrand disease (VWD) is another prevalent congenital bleeding disorder, impacting around 1 in 1000 individuals and up to 1 in 100 with low von Willebrand factor (VWF) levels.
2. Thrombotic Thrombocytopenic Purpura (TTP): TTP is a rare blood disorder marked by the accumulation of blood clots in the body's tiny blood arteries, which can harm organs and lower platelet counts.
3. Sickle Cell Disease: A genetic illness, sickle cell disease, impacts the oxygen-carrying protein in red blood cells, hemoglobin.
4. Idiopathic Thrombocytopenic Purpura (ITP): This autoimmune condition is characterized by a low platelet count, resulting in easy bruising and bleeding and an increased risk of bleeding complications.
5. Myelodysplastic Syndromes (MDS): MDS is a collection of illnesses marked by aberrant bone marrow synthesis of blood cells, resulting in low concentrations of one or more blood cell types (platelets, white blood cells, or red blood cells).
What Are Emerging Therapies for Rare Blood Disorders?
The following are the emerging therapies for rare blood disorders:
-
Novel treatments such as zymogen-like factor IXa and Xa molecules are under development as bypass agents. At the same time, Emicizumab, a bispecific antibody, has shown effectiveness in a phase 3 trial for individuals with hemophilia A and inhibitors.
-
Additionally, ongoing research targets tissue factor pathway inhibitors, the protein C/S system, and antithrombin with new compounds to modulate the hemostatic balance.
-
Modified factor VIII molecules are also being explored for their potential to prevent and eliminate inhibitor antibodies in hemophilia A.
-
Notably, the approval of the first recombinant von Willebrand factor (VWF) product, devoid of factor VIII and featuring unique VWF multimer content, marks a significant milestone. These innovative approaches hold promise for offering improved administration routes, dosage schedules, and efficacy in preventing and treating bleeding episodes in congenital bleeding disorders.
-
The treatment landscape for bleeding disorders has evolved significantly over the past two centuries.
-
In 1840, Lane pioneered whole blood transfusion as a rudimentary treatment, albeit with limited efficacy. The concept of replacing deficient clotting factors was recognized, but whole blood lacked sufficient quantities of specific factors.
-
Plasma fractionation advanced dramatically in the 1950s and 1960s. Judith Graham Pool's discovery of high concentrations of FVIII and VWF in frozen plasma precipitate greatly improved replacement therapy for hemophilia and VWD. Subsequently, in the 1970s, desmopressin's ability to release stored VWF and FVIII introduced a novel treatment approach for mild cases.
-
Further innovations in plasma fractionation led to highly enriched FVIII, FIX, and VWF concentrates, facilitating a shift from episodic to prophylactic replacement therapy and significantly enhancing bleed prevention and clinical outcomes.
-
However, this progress was marred by the HIV and viral hepatitis infections transmitted through plasma-derived products in the 1980s. Improved viral testing and recombinant protein development subsequently mitigated this risk.
-
The U.S. Food and Drug Administration approved TAK-755 (known commercially as Adzynma) in November 2023 as the inaugural therapy for a rare yet potentially fatal blood ailment.
This recent treatment approval signifies the second occasion in Dr. David Ginsburg's career, where he contributed to bringing an FDA-approved medication to market without initially targeting a particular disease.
With the gene and protein identified, producing a purified form of ADAMTS13, also known as the recombinant protein, became feasible. The U-M Office of Tech Transfer (now Innovation Partnerships) facilitated licensing the ADMATS13 sequence to Baxter International (now Takeda), laying the groundwork for the new FDA-approved treatment. Since the early 1980s, individuals with congenital TTP have received treatment using plasma derived from healthy human blood donors. While this approach has significantly reduced the disease's fatality rate from around 90% to 10 to 20%, it is not devoid of risks.
What Are the Advantages of Emerging New Therapies for Blood Disorders?
The primary advantage of the recombinant protein over human plasma is its purity and clarity. With this new treatment, there is precise control over the substance administered to the patient, minimizing the risk of exposure to other substances that may be present in human plasma. The research on ADAMTS13 continues to shape Ginsburg's research endeavors and Levy's professional trajectory, even two decades later.
Scientists in the Ginsburg laboratory still utilize animal models of TTP to explore novel inquiries regarding clotting mechanisms and blood vessel functionality. Levy emphasizes that the discovery, coupled with the fundamental scientific skills acquired, paved the way for a career in the industry.
Although engaged in basic research, the critical thinking skills cultivated through research under David's guidance are integral to daily work, asserts. Bioengineering breakthroughs have yielded recombinant FVIII and FIX therapeutics with extended half-lives, reducing the burden of prophylaxis and improving hemostatic efficacy.
Recent hemophilia gene therapy trials have shown promising results, achieving perpetual replacement therapy through liver-directed targeting with adeno-associated viral vectors, offering potentially curative levels of FVIII and FIX.
Conclusion
In conclusion, emerging new therapies for rare blood disorders have many advantages and have shown results in many patients. While the focus of hemophilia treatment has historically centered on replacing deficient coagulation proteins, advancements in recombinant technology and coagulation biochemistry understanding are reshaping the treatment paradigm.
Novel therapeutics with alternative delivery modes, innovative targets, and improved pharmacokinetic profiles are emerging, promising transformative approaches for hemophilia and other bleeding disorders.
